Drug Trial Radar · NCT07738341
GB268 Monotherapy or Combination Therapy for Locally Advanced/Metastatic Breast Cancer (Phase Ib/Ⅱ)
Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
270
Planned (sponsor's estimate)
Start
Jul 28, 2026
Primary completion
Aug 1, 2029
Study completion Aug 1, 2030
Sponsor
- Lead sponsor
- Eddingpharm (Zhuhai) Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 31, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase Ib/II, open-label, multi-cohort, multi-center study to evaluate the safety, tolerability, and preliminary anti-tumor activity of GB268, a biological product, as monotherapy or in combination with other therapies in patients with locally advanced unresectable or metastatic breast cancer.
Conditions
- Breast Cancer (Locally Advanced or Metastatic)
Interventions
GB268Drug
GB268 is a tri-specific antibody targeting PD-1, CTLA-4, and VEGF. It is designed to block immune checkpoints (PD-1/CTLA-4) to enhance T-cell-mediated anti-tumor immune responses and simultaneously inhibit VEGF-mediated tumor angiogenesis
Nab-PaclitaxelDrug
Nab-Paclitaxel is a microtubule-stabilizing agent formulated as albumin-bound nanoparticles for IV administration.
Datopotamab Deruxtecan (Dato-DXd)Drug
Datopotamab Deruxtecan is an ADC targeting Trop-2, consisting of a monoclonal antibody linked to a topoisomerase I inhibitor payload.
Sacituzumab TirumotecanDrug
A Trop-2-directed Antibody-Drug Conjugate \[ADC\] consisting of a humanized anti-Trop-2 monoclonal antibody covalently linked to a topoisomerase I inhibitor payload.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose-Limiting Toxicities [DLTs] (Phase Ib)Time frame: Within 21 days after first dose
- Objective Response Rate [ORR] (Phase II)Time frame: Up to approximately 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Cancer Hospital, Chinese Academy of Medical Sciences
Beijing, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.